HOLX Quote, Financials, Valuation and Earnings

Inari Medical has a net margin of 18.08% compared to Hologic's net margin of -11.97%. Hologic's return on equity of 16.05% beat Inari Medical's return on equity of -17.68%.

Hologic has a consensus price target of $85.85, signalling upside risk potential of 18.42%. On the other hand Inari Medical has an analysts' consensus of $66.46 which suggests that it could grow by 24.83%. Given that Inari Medical has higher upside potential than Hologic, analysts believe Inari Medical is more attractive than Hologic.

Hologic has a beta of 0.958, which suggesting that the stock is 4.165% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $988M, which are larger than Inari Medical quarterly revenues of $153.4M. Hologic's net income of $178.6M is higher than Inari Medical's net income of -$18.4M. Notably, Hologic's price-to-earnings ratio is 21.77x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 4.27x versus 5.38x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of 18.08% compared to Hologic's net margin of 99.62%. Hologic's return on equity of 16.05% beat Nuwellis's return on equity of -918.02%.

Hologic has a consensus price target of $85.85, signalling upside risk potential of 18.42%. On the other hand Nuwellis has an analysts' consensus of -- which suggests that it could grow by 1409.43%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Hologic has a beta of 0.958, which suggesting that the stock is 4.165% less volatile than S&P 500. In comparison Nuwellis has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.488%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $988M, which are larger than Nuwellis quarterly revenues of $2.4M. Hologic's net income of $178.6M is higher than Nuwellis's net income of $2.4M. Notably, Hologic's price-to-earnings ratio is 21.77x while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 4.27x versus 0.06x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of 18.08% compared to Hologic's net margin of -27.76%. Hologic's return on equity of 16.05% beat Quanterix's return on equity of -11.45%.

Hologic has a consensus price target of $85.85, signalling upside risk potential of 18.42%. On the other hand Quanterix has an analysts' consensus of $21.80 which suggests that it could grow by 104.7%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Hologic has a beta of 0.958, which suggesting that the stock is 4.165% less volatile than S&P 500. In comparison Quanterix has a beta of 1.300, suggesting its more volatile than the S&P 500 by 29.975%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $988M, which are larger than Quanterix quarterly revenues of $34.1M. Hologic's net income of $178.6M is higher than Quanterix's net income of -$9.5M. Notably, Hologic's price-to-earnings ratio is 21.77x while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 4.27x versus 3.16x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of 18.08% compared to Hologic's net margin of -24.31%. Hologic's return on equity of 16.05% beat Varex Imaging's return on equity of -8.23%.

Hologic has a consensus price target of $85.85, signalling upside risk potential of 18.42%. On the other hand Varex Imaging has an analysts' consensus of -- which suggests that it could grow by 55.79%. Given that Varex Imaging has higher upside potential than Hologic, analysts believe Varex Imaging is more attractive than Hologic.

Hologic has a beta of 0.958, which suggesting that the stock is 4.165% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.736%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $988M, which are larger than Varex Imaging quarterly revenues of $205.7M. Hologic's net income of $178.6M is higher than Varex Imaging's net income of -$50M. Notably, Hologic's price-to-earnings ratio is 21.77x while Varex Imaging's PE ratio is 17.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 4.27x versus 0.72x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.